Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses

Luc Furic, Mark Livingstone, Ryan JO Dowling, N Sonenberg

Research output: Contribution to journalReview ArticleResearchpeer-review

14 Citations (Scopus)

Abstract

Cancer cells are characterized by aberrant growth arising from deregulated signalling pathways. The mammalian target of rapamycin (mTOR) pathway integrates multiple growth signals coming from both intracellular and extracellular cues. In this short review, we summarize what is known about the efficacy of targeting the mTOR pathway to treat cancer patients, and we explain the rationale behind promising new inhibitors that could show more potent tumour growth inhibition than did the first generation of these drugs.
Original languageEnglish
Pages (from-to)68 - 70
Number of pages3
JournalCurrent Oncology
Volume16
Issue number1
Publication statusPublished - 2009
Externally publishedYes

Cite this